Fig 1: Involvement of ELOVL7 in IL-6 and IL-12/IL-23 p40 production in M1-like macrophages. THP-1 cells were treated with PMA (30 ng/ml), and then cells were transfected with ELOVL7 siRNA (20 nM) or negative control siRNA (NC, 20 nM) for 24 h. After the treatment, the cells were treated with LPS and IFN-γ (100 ng/ml each) for 24 h. (A) Effect of ELOVL7 knockdown on ELOVL1, ELOVL5, and ELOVL7 mRNA expression. After the treatment, RT-qPCR was performed. Values (mean ± SEM, n = 3) are expressed as fold changes relative to NC M0 macrophages. NS, not significant. *p<0.05, **p<0.01. (B) ELISA analysis. After the treatment, the conditioned medium was subjected to ELISA. Values (mean ± SEM, n = 3) are expressed as IL-6 or IL-12/IL-23 p40 protein levels (pg/ml). *p<0.05, **p<0.01. (C) Effect of ELOVL7 knockdown on cytokine mRNA expression. After the treatment, RT-qPCR was performed. Values (mean ± SEM, n = 3) are expressed as fold changes relative to NC M1-like macrophages. NS, not significant. *p<0.05, **p<0.01. (D) Effect of ELOVL7 knockdown on macrophage polarization marker CD80 and CD206 mRNA expression. After the treatment, RT-qPCR was performed. Values (mean ± SEM, n = 3) are expressed as fold changes relative to NC M0 macrophages. NS, not significant. *p<0.05, **p<0.01.
Supplier Page from Abcam for Human IL-12/IL-23 p40 ELISA Kit